Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 7/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.37 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321232 | 0.93 | HPGD (0.40) | HPGDSMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL2469201 | 0.84 | HPGD (0.36) | HPGDSMN1; SMN2KDM4ECYP1A2CYP2D6 | |
| SCHEMBL29986014 | 0.81 | KCNA3 (0.50) | HPGDSMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL8335852 | 0.80 | HPGD (0.51) | HPGDSMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL320195 | 0.79 | ADRB2 (0.52) | HPGDKDM4ECYP1A2CYP2D6CYP2C19 | |
| Ethylene SCHEMBL27549601 | 0.79 | HPGD (0.47) | HPGDSMN1; SMN2ADRB2ADRB1ADRB3 | |
| SCHEMBL10785918 | 0.78 | KCNA3 (0.43) | KDM4EALDH1A1 | |
| SCHEMBL11519998 | 0.77 | NFE2L2 (0.63) | HPGDKDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL20869253 | 0.77 | KDM4E (0.59) | HPGDSMN1; SMN2KDM4ECYP1A2CYP2D6 | |
| SCHEMBL19455128 | 0.77 | HPGD (0.52) | HPGDKDM4ECYP1A2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | MISTRY SHAILESH (GB) | 2013-10-03 | — | — | US | disclosed |
| EP-2590937-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | The University Of Nottingham (GB) | 2013-05-15 | — | — | EP | disclosed |
| WO-2012004549-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | THE UNIVERSITY OF NOTTINGHAM (GB) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261178-A1 | PHENOXYPROPANOL DERIVATIVES AND THEIR USE IN TREATING CARDIAC AND CARDIOVASCULAR DISEASES | NR3C2, NPR3, ADRB3 | HPGD 2482/4885SMN1; SMN2 2102/4885KDM4E 4571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.